CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.890
+0.005 (0.27%)
At close: May 12, 2025, 4:00 PM
1.800
-0.090 (-4.78%)
After-hours: May 12, 2025, 6:15 PM EDT
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 233 employees as of December 31, 2024. The number of employees increased by 57 or 32.39% compared to the previous year.
Employees
233
Change (1Y)
57
Growth (1Y)
32.39%
Revenue / Employee
$122,476
Profits / Employee
-$168,489
Market Cap
29.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CASI News
- 16 hours ago - CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - Accesswire
- 5 days ago - CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - Accesswire
- 5 weeks ago - CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - Accesswire
- 6 weeks ago - CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - Accesswire
- 4 months ago - CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Accesswire
- 6 months ago - CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - Accesswire
- 7 months ago - CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Accesswire
- 8 months ago - CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - PRNewsWire